COVID-19 Pneumonia Clinical Trial
Official title:
The Effect of Special Discharge Training Prepared for Geriatric Patients in the COVID-19 Service on Daily Life Activities and Quality of Life
Verified date | May 2023 |
Source | Kilis 7 Aralik University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aimed to evaluate the impact of specialized discharge education on the daily life activities and quality of life of geriatric patients hospitalized in COVID-19 wards. The motivation behind this study stems from the vulnerability of elderly patients during the COVID-19 pandemic and the necessity of tailored education to support their daily life activities and enhance their quality of life after discharge. The primary objective of this article is to determine the specific type of specialized discharge education that geriatric patients in COVID-19 wards require to improve their ability to sustain daily life activities and enhance their quality of life. The central idea of this study is that providing specialized discharge education to geriatric patients in COVID-19 wards can result in improvements in their daily life activities and quality of life. The main findings of the study demonstrate a significant enhancement in daily life activities and quality of life among patients who received specialized discharge education. These individuals exhibited increased independence in mobility, improved performance in daily life activities, and reported an overall improvement in their quality of life. These findings underscore the significance of specialized discharge education for geriatric patients hospitalized in COVID-19 wards and highlight its positive impact on their health outcomes and quality of life.
Status | Completed |
Enrollment | 80 |
Est. completion date | July 1, 2022 |
Est. primary completion date | June 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 65 Years to 99 Years |
Eligibility | Inclusion Criteria: - The inclusion criteria for the study were as follows; Willingness to participate in the research, Age 65 and over, Hospitalized geriatric patients in the pandemic service, Openness to communication and cooperation, Sound mental health, Absence of sensory impairments such as vision, hearing, and speech. Exclusion Criteria: - patients who do not meet the inclusion criteria |
Country | Name | City | State |
---|---|---|---|
Turkey | Islam | Kilis |
Lead Sponsor | Collaborator |
---|---|
Kilis 7 Aralik University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Katz Daily Life Activities Scale (GYA): | The Katz Daily Life Activities Scale (GYA) was developed by Katz and colleagues in 1963 to assess activities essential for daily life. The scale measures the scores of key elements related to daily life activities, such as bathing, dressing, toileting, mobility, continence, and feeding. The GYA index categorizes scores as dependent (0-6 points), partially dependent (7-12 points), and independent (13-18 points). The scale has been translated into Turkish and validated by Yardimci E., with a Cronbach's alpha coefficient of 0.73. Response options in the Katz GYA scale include "independent," "partially dependent," and "dependent." | 0 day | |
Primary | Quality of Life Scale (SF-12): | The SF-12 Quality of Life Scale is a widely used instrument that assesses the quality of life over the past four weeks, encompassing various age and disease groups. The Turkish version of the scale, including its reliability and validity study, was conducted by Soylu and Kütük (2022). The SF-12 consists of 12 questions selected from the SF-36 Quality of Life Scale. It comprises eight sub-dimensions and 12 items, including physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health. The SF-12 yields two summary scores: the Physical Component Summary Score (PCSS) and the Mental Component Summary Score (MCSS). The scale demonstrates a Cronbach's alpha coefficient of 0.72. | 0 day | |
Primary | Katz Daily Life Activities Scale (GYA): | The Katz Daily Life Activities Scale (GYA) was developed by Katz and colleagues in 1963 to assess activities essential for daily life. The scale measures the scores of key elements related to daily life activities, such as bathing, dressing, toileting, mobility, continence, and feeding. The GYA index categorizes scores as dependent (0-6 points), partially dependent (7-12 points), and independent (13-18 points). The scale has been translated into Turkish and validated by Yardimci E., with a Cronbach's alpha coefficient of 0.73. Response options in the Katz GYA scale include "independent," "partially dependent," and "dependent." | 1 month | |
Primary | Quality of Life Scale (SF-12): | The SF-12 Quality of Life Scale is a widely used instrument that assesses the quality of life over the past four weeks, encompassing various age and disease groups. The Turkish version of the scale, including its reliability and validity study, was conducted by Soylu and Kütük (2022). The SF-12 consists of 12 questions selected from the SF-36 Quality of Life Scale. It comprises eight sub-dimensions and 12 items, including physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health. The SF-12 yields two summary scores: the Physical Component Summary Score (PCSS) and the Mental Component Summary Score (MCSS). The scale demonstrates a Cronbach's alpha coefficient of 0.72. | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT04901676 -
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
|
Phase 3 | |
Not yet recruiting |
NCT04534478 -
Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19
|
Phase 4 | |
Active, not recruiting |
NCT05002517 -
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab
|
Phase 3 | |
Completed |
NCT05008393 -
Efficacy of PJS-539 for Adult Patients With COVID-19.
|
Phase 2 | |
Completed |
NCT04569877 -
GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia
|
Phase 2 | |
Not yet recruiting |
NCT05286255 -
Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias
|
Phase 1 | |
Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
Recruiting |
NCT06113432 -
CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study
|
N/A | |
Recruiting |
NCT05042063 -
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
|
||
Recruiting |
NCT04615429 -
Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19
|
Phase 2 | |
Completed |
NCT05047653 -
RALE Versus CORADS/CT-Severity Score in COVID-19
|
||
Active, not recruiting |
NCT05047016 -
Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY
|
N/A | |
Active, not recruiting |
NCT05033847 -
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
|
Phase 2 | |
Recruiting |
NCT06113757 -
Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease
|
N/A | |
Completed |
NCT05504655 -
N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
|
||
Active, not recruiting |
NCT05035524 -
A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19
|
N/A | |
Completed |
NCT05065879 -
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
|
Phase 4 | |
Withdrawn |
NCT04390217 -
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
|
Phase 2 | |
Withdrawn |
NCT04460105 -
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
|
Phase 1 | |
Suspended |
NCT04901689 -
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
|
Phase 3 |